Healthcare / BiotechnologyTokyo
$286.00
-10.00 (-3.38%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-1.4B · quality 37.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
7/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$17.9B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-22.7%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-2.02B · FCF $-1.89B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $2.35B | $23.0M | $1.40B |
| Net Income | $-2.02B | $-2.02B | $168.3M | $-1.95B | $-582.4M |
| EBITDA | $-1.97B | $-1.97B | $218.1M | $-1.90B | $-532.2M |
| EPS | -32.98 | -32.98 | 2.69 | -32.92 | — |
| Operating Margin | — | — | 6.1% | -8620.7% | -42.4% |
| Net Margin | — | — | 7.2% | -8479.7% | -41.6% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.00 | 0.00 | 0.00 |
| Current Ratio | 54.00 | 54.00 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.89B | $-1.89B | $1.13B | $-1.40B | $-609.2M |
| Returns | |||||
| ROE | -22.7% | -22.7% | 1.6% | -20.7% | -5.4% |
| Valuation | |||||
| P/E | — | — | 329.00 | — | — |
| EV/EBITDA | — | — | 207.15 | — | — |
| P/B | 1.97 | 1.97 | 5.34 | 5.60 | 3.57 |
| Growth & Yield | |||||
| Revenue Growth | — | — | 10128.1% | -98.4% | — |
| EPS Growth | -1326.0% | -1326.0% | 108.2% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.2%
Start / end P/E
n/dx → n/dx
EPS bridge
2.69 → -32.98
Residual
-11.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.